|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Gastro-duodenal disease in Africa: Literature review and clinical data from Accra, Ghana显示文摘Gastroduodenal disease(GDD)was initially thought to be uncommon in Africa.Amongst others,lack of access to optimal health infrastructure and suspicion of conventional medicine resulted in the reported prevalence of GDD being significantly lower than that in other areas of the world.Following the increasing availability of flexible upper gastro-intestinal endoscopy,it has now become apparent that GDD,especially peptic ulcer disease(PUD),is prevalent across the continent of Africa.Recognised risk factors for gastric cancer(GCA)include Helicobater pylori(H.pylori),diet,Epstein-Barr virus infection and industrial chemical exposure,while those for PUD are H.pylori,non-steroidal antiinflammatory drug(NSAID)-use,smoking and alcohol consumption.Of these,H.pylori is generally accepted to be causally related to the development of atrophic gastritis(AG),intestinal metaplasia(IM),PUD and distal GCA.Here,we perform a systematic review of the patterns of GDD across Africa obtained with endoscopy,and complement the analysis with new data obtained on premalignant gastric his-topathological lesions in Accra,Ghana which was compared with previous data from Maputo,Mozambique.As there is a general lack of structured cohort studies in Africa,we also considered endoscopy-based hospital or tertiary centre studies of symptomatic individuals.In Africa,there is considerable heterogeneity in the prevalence of PUD with no clear geographical patterns.Furthermore,there are differences in PUD within-country despite universally endemic H.pylori infection.PUD is not uncommon in Africa.Most of the African tertiary-centre studies had higher prevalence of PUD when compared with similar studies in western countries.An additional intriguing observation is a recent,ongoing decline in PUD in some African countries where H.pylori infection is still high.One possible reason for the high,sustained prevalence of PUD may be the significant use of NSAIDs in local or over-the-counter preparations.The prevalence of AG and IM,were similar or modestly higher over rates in western countries but lower than those seen in Asia..In our new data,sampling of 136 patients in Accra detected evidence of pre-malignant lesions(AG and/or IM)in 20 individuals(14.7%).Likewise,the prevalence of pre-malignant lesions,in a sample of 109 patients from Maputo,were 8.3%AG and 8.3%IM.While H.pylori is endemic in Africa,the observed prevalence for GCA is rather low.However,cancer data is drawn from country cancer registries that are not comprehensive due to considerable variation in the availability of efficient local cancer reporting systems,diagnostic health facilities and expertise.Validation of cases and their source as well as specificity of outcome definitions are not explicit in most studies further contributing to uncertainty about the precise incidence rates of GCA on the continent.We conclude that evidence is still lacking to support(or not)the African enigma theory due to inconsistencies in the data that indicate a particularly low incidence of GDD in African countries. | Timothy N Archampong Richard H Asmah Cathy J Richards Vicki J Martin Christopher D Bayliss Edília Botao Leonor David Sandra Beleza Carla Carrilho | 2019 | World Journal of Gastroenterology2019，25，26： | 3 |
| 2 | Accumulation of heparan sulfate proteoglycans in cerebellar senile plaques显示文摘 | Jack H Johanneke K Cathy N M | 2002 | Neurobiol Aging2002，23，4： | 1 |
| 3 | Engineering plants with increased levels of the antioxidant chlomgenic acid显示文摘 | Ricarda N Anthony JM Cathie M | 2004 | Nature Biotechnology2004，22，6： | 1 |
| 4 | Impacts of crop residue management on soil organic matter stocks: A modelling study显示文摘 | Cathy N | 2011 | Ecologi- cal Modelling2011，222，15： | 1 |
| 5 | Transitional care in skilled nursing facilities:a muhiple case study显示文摘 | MARK T CATHI EEN C E MARRY D N | 2016 | BMC HealthServRes2016，，： | 1 |
| 6 | Engineering plants with increased levels of the antioxidant chlorogenic acid显示文摘 | Anthony JM Cathie M | 2004 | Nature Biotechnology2004，22，6： | 1 |
| 7 | Interaction between the homeodomain proteins Cdx2 and HNFla mediates expression of the lactase-phlorizin hydrolase gene显示文摘 | Cathy M Jesper T T Spodsberg N | 2000 | Journal of Biochemical2000，346，： | 1 |
| 8 | Given capsule endoscopy in celiac disease显示文摘 | Rima Petroniene Elena Dubcenco Jeffrey P Baker Ralph E Warren Cathy J Streutker Geoffrey W Gardiner Khursheed N Jeejeebhoy | 2004 | Gastrointestinal Endoscopy Clinics of North Americ2004，，1： | 1 |
| 9 | Extended bioremedi- ation of PAH/PCP contaminated soils from the POPILE wood treatment facility 显示文摘 | Hansen L D Cathy N Dave R | 2004 | Chemosphere2004，54，10： | 1 |
| 10 | Dependence structure between the equity market and the foreign exchange market - A copula ap- proach显示文摘 | Cathy N | 2010 | Journal of International Money and Finance2010，，： | 1 |
| 11 | Interaction between the homeodomain proteins Cdx2 and HNF1 a mediates expression of the lactase-phlorizin hydrolase gene 显示文摘 | CATHY M JESPER T SPODSBERG T N | 2000 | J Biol Chem2000，346，： | 1 |
| 12 | Brand eq- uity, brand preference, and purchase Intent 显示文摘 | COBB W CATHY J RUBBLE C A DONTHU N | 1995 | Journal of Advertising1995，35，3： | 1 |
| 13 | Engineering plants with increased levels of the antioxidant chlorogenic acid显示文摘 | Ricarda N Anthony J M Cathie M | 2004 | Nature Biotechnology2004，22，6： | 1 |
| 14 | Crohn's disease genotypes of patients in remission vs relapses after infliximab discontinuation显示文摘AIM:To investigate genetic differences between Crohn's disease(CD) patients with a sustained remission vs relapsers after discontinuing infliximab while in corticosteroid-free remission.METHODS:Forty-eight CD patients received infliximab and were in full corticosteroid-free clinical remission but then discontinued infliximab for reasons other than a loss of response,were identified by review of an electronic database and charts.Infliximab-associated remission was defined as corticosteroid-free plus normalization of clinical disease activity [CD activity index(CDAI) < 150] during follow-up visits based on physician global assessments.A CD relapse(loss of infliximab-induced remission) was clinically defined as a physician visit for symptoms of disease activity(CDAI > 220) and a therapeutic intervention with CD medication(s),or a hospitalization with complications related to active CD.Genetic analyses were performed on samples from 14 patients(n = 6 who had a sustained long term remission after stopping infliximab,n = 8 who rapidly relapsed after stopping infliximab).Nucleotide-binding oligomerization domain 2(NOD2)/caspase activation recruitment domain 15(CARD15) polymorphisms(R702W,G908R and L1007fs) and the inflammatory bowel disease 5(IBD5) polymorphisms(IGR2060a1 and IGR3081a1) were analyzed in each group.RESULTS:Five single nucleotide polymorphisms of IBD5 and NOD2/CARD15 genes were successfully analyzed for all 14 subjects.There was no significant increase in frequency of the NOD2/CARD15 polymorphisms(R702W,G908R and L1007fs) and the IBD5 polymorphisms(IGR2060a1 and IGR3081a1) in either group of patients;those whose disease relapsed rapidly or those who remained in sustained long term remission following the discontinuation of infliximab.Nearly a third of patients in full clinical remission who stopped infliximab for reasons other than loss of response remained in sustained clinical remission,while two-thirds relapsed rapidly.There was a marked difference in the duration of clinical remission following discontinuance of infliximab between the two groups.The patients who lost remission did so after 1.0 years ± 0.6 years,while those still in remission were at the time of this study,8.1 years ± 2.6 years post-discontinuation of infliximab,P < 0.001.The 8 patients who had lost remission after discontinuing infliximab had a mean number of 5 infusions(range 3-7),with a mean treatment time of 7.2 mo(range 1.5 mo-15 mo).The mean duration of time from the last infusion of infliximab to the time of loss of remission was 382 d(range 20 d-701 d).The 6 patients who remained in remission after discontinuing infliximab had a mean number of 6 infusions(range 3-12),with a mean treatment duration of 12 mo(range 3.6 mo-32 mo)(P = 0.45 relative to those who lost remission).CONCLUSION:There are no IBD5 or NOD2/CARD15 mutations that predict which patients might have sustained remission and which will relapse rapidly after stopping infliximab. | Cathy Lu Alistair Waugh Robert J Bailey Raeleen Cherry Levinus A Dieleman Leah Gramlich Kata Matic Mario Millan Karen I Kroeker Daniel Sadowski Christopher W Teshima Dennis Todoruk Clarence Wong Karen Wong Richard N Fedorak | 2012 | World Journal of Gastroenterology2012，18，36： | 1 |
| 15 | The dependence structure between the Canadian stock market and the USD/CAD ex- change rate : a copula approach 显示文摘 | LEO M CATHY N | 2010 | Canadian Journal of Economics2010，43，3： | 1 |
| 16 | The Global Soil Mycobiome consortium dataset for boosting fungal diversity research显示文摘Fungi are highly important biotic components of terrestrial ecosystems,but we still have a very limited understanding about their diversity and distribution.This data article releases a global soil fungal dataset of the Global Soil Mycobiome consortium(GSMc)to boost further research in fungal diversity,biogeography and macroecology.The dataset comprises 722,682 fungal operational taxonomic units(OTUs)derived from PacBio sequencing of full-length ITS and 18S-V9 variable regions from 3200 plots in 108 countries on all continents.The plots are supplied with geographical and edaphic metadata.The OTUs are taxonomically and functionally assigned to guilds and other functional groups.The entire dataset has been corrected by excluding chimeras,index-switch artefacts and potential contamination.The dataset is more inclusive in terms of geographical breadth and phylogenetic diversity of fungi than previously published data.The GSMc dataset is available over the PlutoF repository. | Leho Tedersoo Vladimir Mikryukov Sten Anslan Mohammad Bahram Abdul Nasir Khalid Adriana Corrales Ahto Agan Aída-M.Vasco-Palacios Alessandro Saitta Alexandre Antonelli Andrea C.Rinaldi Annemieke Verbeken Bobby P.Sulistyo Boris Tamgnoue Brendan Furneaux Camila Duarte Ritter Casper Nyamukondiwa Cathy Sharp César Marín D.Q.Dai Daniyal Gohar Dipon Sharmah Elisabeth Machteld Biersma Erin K.Cameron Eske De Crop Eveli Otsing Evgeny A.Davydov Felipe E.Albornoz Francis Q.Brearley Franz Buegger Genevieve Gates Geoffrey Zahn Gregory Bonito Indrek Hiiesalu Inga Hiiesalu Irma Zettur Isabel C.Barrio Jaan Pärn Jacob Heilmann-Clausen Jelena Ankuda John Y.Kupagme Joosep Sarapuu Jose G.Maciá-Vicente Joseph Djeugap Fovo József Geml Juha M.Alatalo Julieta Alvarez-Manjarrez Jutamart Monkai Kadri Põldmaa Kadri Runnel Kalev Adamson Kari A.Bråthen Karin Pritsch Kassim I.Tchan Kęstutis Armolaitis Kevin D.Hyde Kevin K.Newsham Kristel Panksep Lateef A.Adebola Louis J.Lamit Malka Saba Marcela Eda Silva Cáceres Maria Tuomi Marieka Gryzenhout Marijn Bauters Miklós Bálint Nalin Wijayawardene Niloufar Hagh-Doust Nourou S.Yorou Olavi Kurina Peter E.Mortimer Peter Meidl RHenrik Nilsson Rasmus Puusepp Rebeca Casique-Valdés Rein Drenkhan Roberto Garibay-Orijel Roberto Godoy Saleh Alfarraj Saleh Rahimlou Sergei Põlme Sergey V.Dudov Sunil Mundra Talaat Ahmed Tarquin Netherway Terry W.Henkel Tomas Roslin Vladimir E.Fedosov Vladimir G.Onipchenko WAErandi Yasanthika Young Woon Lim Meike Piepenbring Darta Klavina Urmas Kõljalg Kessy Abarenkov | 2021 | Fungal Diversity2021，，6： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员